Mark Robert Baker, CEO at PROGENICS PHARMACEUTICALS INC (PGNX), bought 343 shares at $10.19 ($3K) on 2012-03-28, disclosed to the SEC on 2012-03-29.
Scheduled purchase ($3k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $10.00 | 100 | $1K | 28.8% |
| 2 | $10.18 | 103 | $1K | 30.2% |
| 3 | $10.19 | 140 | $1K | 41.1% |
| Total | $10.13 avg | 343 | $3K | 100% |
| Filing → |
| PGNX | BUY | 2013-01-23 | $3K | — | Filing → |
| PGNX | BUY | 2012-12-26 | $3K | — | Filing → |
| PGNX | BUY | 2012-11-30 | $3K | — | Filing → |